Melanoma-associated antigen 1 (MAGE-A1) antigen-derived epitope (MAGE-A1 epitope)

Melanoma-associated antigen 1 (MAGE-A1) is a member of the Type I MAGE family and is classified as a cancer/testis (CT) antigen due to its restricted expression in the testis and its aberrant re-expression in various malignancies, including melanoma, lung, and breast cancers. MAGE-A1-derived epitopes are short peptides, such as the HLA-A1-restricted EADPTGHSY or HLA-A3-restricted MAGE-A1(96-104), that are presented by Major Histocompatibility Complex (MHC) Class I molecules on the tumor cell surface. These epitopes are recognized by cytotoxic T lymphocytes (CTLs), making them ideal targets for cancer immunotherapies like peptide vaccines and adoptive T-cell therapies (TCR-T and CAR-T). Biologically, MAGE-A1 functions as a transcriptional repressor by interacting with SKIP and HDAC1, and it can modulate ubiquitin ligase activity to promote tumor cell survival. Targeting these epitopes aims to exploit the immune-privileged nature of the testis to achieve high tumor specificity. However, therapeutic challenges include the potential for cross-reactivity with other MAGE family members and the downregulation of MHC molecules by tumor cells to evade immune detection.

Other names

MAGE-1 epitopeAntigen MZ2-E epitopeCancer/testis antigen 1.1 epitopeMAGE-A1 peptideMelanoma-associated antigen 1 peptideMAGE-A1-derived peptide

Induction of T-cell mediated cytotoxicity through the recognition of peptide-MHC complexes on the surface of tumor cells; epigenetic induction of antigen expression using demethylating agents.